Allergan Inc v. Galderma Group AG

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Allergan, Inc. and AbbVie Inc. (Delaware)
  • Defendant: Galderma Group AG (Switzerland), Galderma S.A. (Switzerland), Galderma Laboratories, L.P. (Texas), and Q-Med AB (Sweden)
  • Plaintiff's Counsel: Paul Hastings LLP
• Case Identification: 3:26-cv-02420, N.D. Tex., 07/21/2026
• Venue Allegations: Venue is alleged to be proper as to Defendant Galderma Laboratories, L.P. because it is a Texas limited partnership with its principal place of business in Dallas, Texas. For the foreign defendants, venue is alleged to be proper in any district where they are subject to personal jurisdiction.
• Core Dispute: Plaintiff alleges that the ornamental design of Defendant's new Restylane® line of syringes infringes five of Plaintiff's design patents covering its Juvéderm® Collection of Fillers syringes.
• Technical Context: The technology at issue is the ornamental, non-functional design of syringes used to administer hyaluronic acid-based dermal fillers in the highly competitive aesthetic medicine market.
• Key Procedural History: The complaint alleges that after Plaintiff launched its redesigned Juvéderm® syringes around 2018, Defendants, who had previously used a dissimilar design, developed and launched a "copycat" syringe. Plaintiff highlights that on February 9, 2023, Defendants cited at least three of the asserted patents in an Information Disclosure Statement filed with the U.S. Patent and Trademark Office, an event that may be significant for the allegation of willful infringement.

Case Timeline

Date	Event
2017-03-24	Earliest Priority Date for all Asserted Patents
2019-11-05	U.S. Patent Nos. D865,948, D865,949, and D865,950 Issued
2019-11-12	U.S. Patent No. D866,753 Issued
2019-11-19	U.S. Patent No. D867,582 Issued
2023-02-09	Defendants allegedly cite Asserted Patents in an IDS filing
2025-07-02	FDA receives supplement for Defendant's new syringe
2026-01-29	FDA decision date for Defendant's new syringe
2026-02-25	Defendants announce regulatory approval for new Restylane® Syringe
2026-02-25	Earliest alleged import date of Accused Product
2026-07-21	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. D865,948 - "Syringe Device"

The Invention Explained

• Problem Addressed: The complaint asserts that prior to its innovation, the dermal filler market was characterized by "conventional, utilitarian syringe presentations" that lacked a distinctive visual identity Compl. ¶29
• The Patented Solution: The patent claims a new, original, and ornamental design for a syringe device, which is defined by the visual characteristics depicted in its figures D''948 Patent, Figs. 1-7 The complaint alleges that features such as the "distinctive visual curvatures and sculptural silhouette of the finger flanges, the smooth contoured profile of the barrel, [and] the stylized shape of the plunger head" create a unique aesthetic impression Compl. ¶30
• Technical Importance: The complaint alleges the design's importance is not functional but aesthetic and commercial, serving to create a "visual hallmark associated with the Juvéderm® brand" that is "immediately recognizable to injectors and patients alike" Compl. ¶24 Compl. ¶31

Key Claims at a Glance

• Design patents contain a single claim. The asserted claim is for "The ornamental design for a syringe device, as shown and described" D'948 Patent, claim Compl. ¶36
• The elements of the claim are the visual features of the syringe shown in solid lines in the patent's drawings, including:
  • A plunger head with a textured, circular top surface.
  • A pair of curved, outwardly flaring finger flanges with a smooth, sculptural shape.
  • The contoured profile of the syringe body where it meets the finger flanges.
  • The overall visual relationship and proportions of these elements.

U.S. Patent No. D865,949 - "Syringe Device"

The Invention Explained

• Problem Addressed: As with the D'948 Patent, the design is positioned as a departure from the "utilitarian syringe presentations that had long characterized the dermal filler industry" Compl. ¶29
• The Patented Solution: The ''949 Patent claims another ornamental design for a syringe device, defined by the drawings provided (D'949 Patent, Figs. 1-7). While visually similar to the D'948 patent, it represents a distinct design, with subtle differences in the contours and shape of the finger flanges and body, creating a slightly different overall aesthetic impression Compl. ¶30 Compl. ¶40
• Technical Importance: The design contributes to the overall "distinctive visual appearance" of the Juvéderm® product line, which the complaint alleges has cultivated significant brand recognition and goodwill in the aesthetics market Compl. ¶27 Compl. ¶31

Key Claims at a Glance

• The patent asserts a single claim for "The ornamental design for a syringe device, as shown and described" (D'949 Patent, claim; Compl. ¶40).
• The elements of this claim are the visual features shown in the patent's drawings, which present a variation on the design theme with specific contours for the plunger, finger flanges, and barrel.

U.S. Patent No. D865,950 - "Syringe Device"

• Technology Synopsis: The patent protects another distinct ornamental design for a syringe device, intended to provide a unique aesthetic for dermal filler products and distinguish them from conventional, utilitarian syringes Compl. ¶29 Compl. ¶44
• Asserted Claims: The single claim for the ornamental design as shown and described Compl. ¶44
• Accused Features: The overall visual appearance of the accused Restylane® Syringe is alleged to be substantially similar to the patented design Compl. ¶96

U.S. Patent No. D866,753 - "Syringe Device"

• Technology Synopsis: The patent protects an additional ornamental design for a syringe device, contributing to a family of designs with a novel and distinctive visual appearance in the dermal filler marketplace Compl. ¶29 Compl. ¶48
• Asserted Claims: The single claim for the ornamental design as shown and described Compl. ¶48
• Accused Features: The overall visual impression of the accused Restylane® Syringe is alleged to be substantially similar to the patented design Compl. ¶106

U.S. Patent No. D867,582 - "Syringe Device"

• Technology Synopsis: The patent protects a further ornamental design for a syringe device, which includes multiple embodiments showing variations of the design theme Compl. ¶52 D''582 Patent, Figs. 1-42
• Asserted Claims: The single claim for the ornamental design as shown and described Compl. ¶52
• Accused Features: The overall visual appearance of the accused Restylane® Syringe is alleged to be substantially similar to the patented design Compl. ¶116

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendants' "updated Restylane® syringe," also referred to as the "Restylane® Syringe" Compl. ¶57 Compl. ¶62

Functionality and Market Context

• The accused product is a syringe used to deliver Defendants' Restylane® line of dermal fillers Compl. ¶53 The complaint alleges that for years, Defendants used a syringe with a "markedly different appearance" before adopting the accused design Compl. ¶5 Compl. p. 3
• Plaintiff alleges that Defendants' launch of the new syringe, which it announced in February 2026, was a "calculated decision" to "copy Allergan's proprietary, patent-protected designs" Compl. ¶6 Compl. ¶59 The complaint presents an image from Defendants' Instagram account showcasing the accused syringe Compl. p. 17 It also provides a graphic from the accused product's "Instructions for Use" to show it is being marketed for purchase in the United States Compl. p. 18
• The complaint alleges the new design is intended to "compete with Allergan in the dermal filler market with a syringe that closely mimics and infringes the Asserted Patents" Compl. ¶56

IV. Analysis of Infringement Allegations

The complaint alleges that the accused Restylane® Syringe is "substantially similar in its overall visual impression to the design claimed" in each of the asserted patents, such that an ordinary observer would be deceived Compl. ¶76 Compl. ¶86 Compl. ¶96 Compl. ¶106 Compl. ¶116 The core of this allegation is captured in side-by-side visual comparisons provided for each asserted patent.

D865,948 Infringement Allegations

Claim Element (from the Single Design Claim)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
The ornamental design for a syringe device, as shown and described.	The overall visual impression of the accused Restylane® Syringe, which is alleged to be substantially similar to the patented design.	¶76	D'948 Patent, col. 1:47-48
The ornamental design of the plunger head.	The accused syringe allegedly features a plunger head with a similar shape, proportions, and top surface appearance.	¶76; p. 22	D'948 Patent, col. 1:49-62; D'948 Patent, Fig. 1
The ornamental design of the finger flanges.	The accused syringe allegedly incorporates curved, sculptural finger flanges that mimic the overall shape and contours of the patented design.	¶76; p. 22	D'948 Patent, col. 1:49-62; D'948 Patent, Fig. 1
The ornamental design of the syringe body profile.	The profile of the accused syringe's body, particularly the grip area below the flanges, is alleged to be visually similar to that shown in the patent.	¶76; p. 22	D'948 Patent, col. 1:49-62; D'948 Patent, Fig. 1

D865,949 Infringement Allegations

Claim Element (from the Single Design Claim)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
The ornamental design for a syringe device, as shown and described.	The overall visual impression of the accused Restylane® Syringe, which is alleged to be substantially similar to the distinct design claimed in the '949 Patent.	¶86	D'949 Patent, col. 1:47-48
The specific ornamental features shown in Figure 1 of the patent.	The complaint provides a side-by-side comparison, alleging that the combination of the plunger, flanges, and body of the accused syringe creates a visual impression that is substantially similar to the claimed design.	¶86; p. 24	D'949 Patent, col. 1:49-62; D'949 Patent, Fig. 1

Identified Points of Contention

• Scope Questions: The central question for infringement is whether an ordinary observer, familiar with the prior art, would find the accused Restylane® syringe design substantially the same as the designs claimed in the asserted patents. The court's analysis may focus on whether the claimed designs are considered a broad aesthetic concept or a collection of very specific, narrow ornamental features.
• Technical Questions: A key factual dispute will likely center on the visual effect of any differences between the products. While the complaint characterizes differences as "minor" Compl. ¶76, Defendants may argue that variations in curvature, proportion, texture, or the shape of the flanges are significant enough to create a different overall visual impression, especially when viewed in light of the prior art. The complaint provides a visual of Defendants' previous, non-infringing syringe design, which may serve as a key point of reference for the scope of the prior art Compl. p. 3

V. Key Claim Terms for Construction

In design patent cases, claim construction is typically not performed with verbal descriptions, as the claim is defined by the drawings. However, the scope of the claim is a central issue.

• The Term: "the ornamental design for a syringe device"
• Context and Importance: This phrase constitutes the entirety of the claim in each asserted patent. The visual scope of this "ornamental design," as defined by the solid lines in the patent drawings and understood in the context of the prior art, will be determinative for infringement. Practitioners may focus on how the prior art informs the perspective of the "ordinary observer" and narrows or broadens the scope of protection afforded to the claimed designs.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patents claim the overall appearance of the device as shown. A party could argue that the claim protects the holistic aesthetic impression created by the combination of the stylized plunger, sculptural flanges, and contoured body, rather than any single feature in isolation D'948 Patent, Fig. 1
  • Evidence for a Narrower Interpretation: The scope is expressly limited to the "ornamental" design, not any functional aspects of the syringe. Further, the patents explicitly disclaim features shown in broken lines, such as the needle and internal components, thereby narrowing the claim to the specific external surfaces depicted D'948 Patent, description The existence of multiple, similar design patents in the family may also be used to argue that each patent covers only the very specific embodiment shown.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that Defendants have induced and/or will induce infringement by injectors who "use" the accused Restylane® Syringe. This is based on allegations that Defendants provide the syringes with "intent, knowledge, and encouragement" for their use Compl. ¶78 Compl. ¶88
• Willful Infringement: Plaintiffs allege that Defendants' infringement has been "deliberate and willful" Compl. ¶83 This allegation is supported by the claim that Defendants are "a sophisticated, multinational competitor in the same dermal filler market" and had specific knowledge of the patents Compl. ¶58 The complaint specifically alleges that on February 9, 2023, Defendants cited the '949, ''753, and '582 patents in an Information Disclosure Statement filed with the USPTO, suggesting pre-suit knowledge of at least some of the patents-in-suit Compl. ¶58

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of visual perception: would an ordinary observer in the field of aesthetic medicine, giving the attention a purchaser usually gives, be deceived into believing the accused Restylane® syringe is the same as the patented Juvéderm® designs, or are the differences sufficient to create a distinct overall impression?
• A second critical question concerns the impact of the prior art: how will the court and jury view the scope of the asserted patents in light of other syringe designs that existed before March 2017? The breath of the prior art will directly influence whether the claimed designs are seen as a broad, pioneering aesthetic or a narrow improvement over existing designs.
• Finally, a key question for damages will be intent: do the allegations of Defendants' sophistication, their documented knowledge of the asserted patents via an IDS filing, and the alleged "copying" of the design demonstrate the kind of deliberate or egregious conduct required for a finding of willful infringement and potential enhancement of damages?